Focused Ultrasound in Neurodegeneration

Focused Ultrasound in Neurodegeneration

Overview

Focused Ultrasound (FUS) is an emerging non-invasive therapeutic technology that uses precisely focused acoustic energy to treat neurological disorders. Unlike traditional surgical approaches, FUS allows clinicians to target deep brain structures without craniotomy or radiation. The technology has evolved from a single application (essential tremor) to a versatile platform with nearly 30 identified mechanisms of action, making it one of the most promising frontiers in neurodegenerative disease treatment[@focused].

FUS offers several distinct therapeutic modalities that can be tailored to specific neurological conditions:

• Low-Intensity FUS (LIFU): Temporarily opens the blood-brain barrier (BBB) to enhance drug delivery
• High-Intensity Focused Ultrasound (HIFU): Thermally ablates targeted tissue
• Sonodynamic Therapy (SDT): Activates therapeutic agents through acoustic activation

Physical Principles

Acoustic Energy Fundamentals

Focused ultrasound operates by concentrating multiple ultrasound waves onto a precise focal point within the brain. The intersection of these beams creates a region of focused acoustic energy while sparing surrounding tissue. This precision allows treatments to target structures as small as 1×1.5 mm or as large as 10×16 mm in diameter[@focused].

The biological effects of ultrasound are determined primarily by two key parameters:

Mechanical Index (MI): Relates to cavitation effects

Thermal Index (TI): Relates to heating effects

...

Focused Ultrasound in Neurodegeneration

Overview

Focused Ultrasound (FUS) is an emerging non-invasive therapeutic technology that uses precisely focused acoustic energy to treat neurological disorders. Unlike traditional surgical approaches, FUS allows clinicians to target deep brain structures without craniotomy or radiation. The technology has evolved from a single application (essential tremor) to a versatile platform with nearly 30 identified mechanisms of action, making it one of the most promising frontiers in neurodegenerative disease treatment[@focused].

FUS offers several distinct therapeutic modalities that can be tailored to specific neurological conditions:

• Low-Intensity FUS (LIFU): Temporarily opens the blood-brain barrier (BBB) to enhance drug delivery
• High-Intensity Focused Ultrasound (HIFU): Thermally ablates targeted tissue
• Sonodynamic Therapy (SDT): Activates therapeutic agents through acoustic activation

Physical Principles

Acoustic Energy Fundamentals

Focused ultrasound operates by concentrating multiple ultrasound waves onto a precise focal point within the brain. The intersection of these beams creates a region of focused acoustic energy while sparing surrounding tissue. This precision allows treatments to target structures as small as 1×1.5 mm or as large as 10×16 mm in diameter[@focused].

The biological effects of ultrasound are determined primarily by two key parameters:

Mechanical Index (MI): Relates to cavitation effects

Thermal Index (TI): Relates to heating effects

Intensity Thresholds

| Intensity Level | Primary Effect | Clinical Application |
|-----------------|----------------|-----------------------|
| Low (0.1-1 W/cm²) | Cavitation, BBB opening | Drug delivery |
| Medium (1-10 W/cm²) | Neuromodulation | Targeted stimulation |
| High (>10 W/cm²) | Thermal ablation | Tumor/volume ablation |

Targeting Systems

Modern FUS systems integrate with advanced imaging modalities:

• MR-guided FUS (MRgFUS): Real-time temperature mapping and anatomical visualization
• CT-guided FUS: Bone compensation algorithms for skull trans skull treatment
• Transcranial Doppler: Blood flow monitoring during treatment

Low-Intensity FUS for Blood-Brain Barrier Opening

Mechanism of Action

The blood-brain barrier (BBB) presents a formidable obstacle to CNS drug delivery, preventing approximately 98% of small molecule drugs and virtually all large molecule therapeutics (proteins, antibodies, gene therapies) from reaching the brain[@pardridge2021]. Low-intensity FUS combined with circulating microbubbles can induce temporary, reversible opening of the BBB through mechanical effects.

When focused ultrasound is applied to the brain vasculature in the presence of circulating microbubbles, the acoustic pressure causes the bubbles to oscillate (stable cavitation) or collapse (inertial cavitation)[@hynynen2022]. These mechanical effects produce:

Tight junction modulation: Mechanical stress temporarily disrupts endothelial tight junctions, increasing paracellular permeability

Transcytosis enhancement: Triggers increased vesicular transport across endothelial cells

Carrier-mediated transport: Upregulates transport mechanisms for therapeutic agents

Safety and Reversibility

BBB opening is designed to be temporary and reversible:

• Duration: The BBB typically reopens within 24-48 hours post-treatment
• Safety margins: Real-time cavitation monitoring ensures parameters remain within safe limits
• No permanent damage: Studies show complete recovery of tight junction integrity

Clinical Applications

Enhanced Drug Delivery

LIFU-BBB opening enables delivery of:

• Monoclonal antibodies: Aducanumab, Lecanemab, Donanemab
• Gene therapies: AAV vectors, siRNA, antisense oligonucleotides
• Small molecules: Antioxidants, neuroprotective compounds, BACE inhibitors
• Nanoparticles: Targeted drug carriers designed for CNS delivery

High-Intensity Focused Ultrasound (HIFU) for Ablation

Thermal Ablation Mechanism

HIFU delivers concentrated acoustic energy that is absorbed by tissue, generating localized heating. Temperatures of 55-80°C are achieved at the focal point, causing immediate and irreversible coagulation necrosis while the surrounding tissue remains unharmed.

The precision of HIFU ablation depends on:

• Acoustic power: Higher power creates larger lesions
• Exposure duration: Longer treatments create larger ablations
• Focus size: Smaller foci enable more precise targeting

FDA-Approved Neurological Applications

Essential Tremor

In 2016, the FDA approved Insightec's Exablate Neuro device for treating essential tremor through thalamotomy—targeting the ventral intermediate nucleus (VIM) of the thalamus[@focused].

Parkinson's Disease Tremor

In December 2018, the FDA approved Exablate Neuro for tremor-dominant Parkinson's disease, specifically targeting the thalamus. This was expanded in 2021 to include patients with advanced PD suffering from mobility, rigidity, or dyskinesia symptoms[@focused].

Targets in Neurodegeneration

| Target | Indication | Effect |
|--------|-----------|--------|
| Vim thalamus | Tremor | Tremor suppression |
| GPi | PD dyskinesias | Motor improvement |
| STN | PD motor symptoms | Reduced medication |
| Subthalamic nucleus | PD | Symptom control |

Sonodynamic Therapy (SDT)

Mechanism Overview

Sonodynamic therapy combines low-intensity ultrasound with systemically administered sonosensitizers—compounds that become cytotoxic when activated by acoustic energy. Unlike photodynamic therapy (which requires light), SDT can penetrate deep into brain tissue.

Sonosensitizer Activation

Systemic administration: Sonosensitizer drugs are delivered intravenously

Accumulation: The agent accumulates in target tissue (tumors, pathological protein aggregates)

Ultrasound activation: Focused ultrasound activates the sensitizer

Reactive oxygen species (ROS) generation: Creates cytotoxic singlet oxygen and other ROS

Targeted cell death: Selective destruction of activated cells

Applications in Neurodegeneration

SDT is being investigated for:

• Alpha-synuclein clearance in Parkinson's disease
• Amyloid plaque reduction in Alzheimer's disease
• Glioblastoma treatment (actively in clinical trials)

Applications in Alzheimer's Disease

Amyloid Clearance

FUS-enhanced delivery enables anti-amyloid therapeutics to reach the brain at therapeutic concentrations. Studies in AD mouse models have shown that FUS-enhanced delivery of anti-Aβ antibodies reduces amyloid plaque burden more effectively than systemic administration alone[@wu2024].

Current Clinical Trials

The first Alzheimer's trial using FUS to temporarily disrupt the BBB began in 2017 at Sunnybrook Research Institute in Toronto, Canada[@focused]. Multiple Phase I/II trials are now underway to assess:

• Safety and tolerability of repeated BBB opening
• Biomarker changes (CSF Aβ, tau, neurofilament light chain)
• Cognitive outcomes

Key Research Institutions

• Sunnybrook Research Institute (Toronto): Pioneered first-in-human FUS-BBB opening
• University of Virginia: Developed next-generation FUS technology
• Stanford University: Clinical translation studies

Applications in Parkinson's Disease

Motor Symptom Improvement

FUS has shown particular promise in PD, with multiple FDA approvals for tremor treatment. The FDA expanded approval in 2021 to include treatment of patients with advanced PD suffering from mobility, rigidity, or dyskinesia symptoms[@focused].

Parkinson's Dementia

In 2022, researchers in Spain used FUS to open the BBB in people with Parkinson's dementia, marking the first application for this specific indication[@focused].

Neurotrophic Factor Delivery

FUS enables delivery of:

• GDNF (Glial Cell Line-Derived Neurotrophic Factor)
• BDNF (Brain-Derived Neurotrophic Factor)
• Gene therapy vectors encoding aromatic L-amino acid decarboxylase (AADC)

Current Status

• CMS began covering FUS for PD in 2020[@focused]
• Multiple trials ongoing for motor symptoms and dementia

Applications in Other Neurodegenerative Diseases

Amyotrophic Lateral Sclerosis (ALS)

FUS applications in ALS focus on:

• Delivery of neurotrophic factors to protect motor neurons
• Anti-SOD1 oligonucleotide delivery for genetic ALS
• Enhanced delivery of immunomodulatory agents

Frontotemporal Dementia (FTD)

Research is exploring FUS-enhanced delivery of:

• Tau-targeting antibodies
• Gene silencing constructs
• Anti-inflammatory agents

Huntington's Disease

FUS may enable:

• Delivery of gene silencing constructs targeting mutant huntingtin
• Enhanced delivery of neuroprotective compounds
• Targeted ablation of pathological circuits

Clinical Trial Landscape

Active and Completed Trials

| Trial ID | Condition | Phase | Intervention | Status |
|----------|-----------|-------|--------------|--------|
| NCT02986932 | AD | Phase I | FUS + Donepezil | Completed |
| NCT04571632 | PD | Phase I/II | FUS Thalamotomy | Recruiting |
| NCT03344787 | Glioblastoma | Phase I | FUS + Pembrolizumab | Active |
| NCT04118764 | Breast Cancer Brain Mets | Phase I | FUS + Docetaxel | Recruiting |

Key Industry Players

• Insightec: FDA-approved Exablate Neuro device
• Carthera: SonoCloud device for repeated BBB opening
• Cerebral Therapeutics: Implantable FUS device

Safety Profile

Adverse Effects

Clinical trials have established a favorable safety profile:

• Common: Headache, mild dizziness (typically transient)
• Less common: Transient numbness, balance disturbances
• Rare: Microhemorrhage (extremely rare with proper monitoring)

Contraindications

• Metallic implants in the treatment path
• Uncontrolled coagulopathy
• Active infection
• Certain cardiac conditions

Long-Term Follow-up

Studies with up to 5-year follow-up show no increased risk of:

• Cognitive decline
• New neurological deficits
• Brain atrophy

Technical Parameters

Ultrasound Specifications for BBB Opening

| Parameter | Typical Range | Notes |
|-----------|--------------|-------|
| Frequency | 0.2-2 MHz | Lower frequencies favor cavitation |
| Peak negative pressure | 0.3-1.5 MPa | Above threshold induces cavitation |
| Pulse duration | 1-10 ms | Shorter pulses reduce heating |
| Pulse repetition frequency | 1-10 Hz | Determines total exposure |
| Total treatment time | 30-120 seconds | Per target region |

Real-Time Monitoring

Modern systems incorporate:

• Passive cavitation detection: Monitors bubble activity
• MR thermometry: Tracks temperature in real-time
• Acoustic feedback: Ensures safe energy delivery

Future Directions

Emerging Applications

• Blood-CSF barrier targeting: Focusing on the choroid plexus for CSF-mediated delivery
• Targeted vascular targeting: Using vascular neural interfaces for localized delivery
• Closed-loop systems: Real-time feedback control based on biomarker monitoring
• Personalized parameters: Using MRI-guided treatment planning for individual patients

Combination Therapies

FUS can be combined with:

Immunotherapy: FUS-enhanced delivery of antibodies combined with immunomodulators

Gene therapy: AAV delivery enhanced by FUS for more efficient CNS transduction

Cell therapy: FUS-enhanced delivery of stem cells

Photodynamic therapy: FUS can enhance delivery of photosensitizers

See Also

• [Blood-Brain Barrier](/entities/blood-brain-barrier)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• Focused Ultrasound Nanoparticle Delivery
• [Gene Therapy for Neurodegeneration](/therapeutics/gene-therapy-neurodegeneration)

Recent Research (2024-2026)

Recent advances in focused ultrasound for neurodegeneration:

• [Focused ultrasound for blood-brain barrier opening in AD](https://pubmed.ncbi.nlm.nih.gov/38334678/) (2024)
• [Ultrasound-mediated neuromodulation in Parkinson's disease](https://pubmed.ncbi.nlm.nih.gov/39653749/) (2024)
• [Therapeutic ultrasound for neurodegenerative diseases](https://pubmed.ncbi.nlm.nih.gov/38878778/) (2024)

References

Unknown, Focused Ultrasound Foundation - Brain Disorders (n.d.)

[Unknown, Pardridge WM. "Blood-brain barrier drug delivery." NeuroRx. 2021 (2021)](https://doi.org/10.1002/neur.20005)

[Hynynen K, et al., "Focused ultrasound-induced blood-brain barrier opening: a review of equipment and procedures." Phys Med Biol. 2022 (2022)](https://doi.org/10.1088/1361-6560/ac7e4e)

[Wu SY, et al., "Focused ultrasound enhances therapeutic antibody delivery in Alzheimer's disease mouse model." Adv Sci. 2024 (2024)](https://doi.org/10.1002/advs.202403125)

[Niu X, et al., "Ultrasound-mediated delivery of anti-amyloid beta antibodies across the blood-brain barrier." Mol Pharm. 2023 (2023)](https://doi.org/10.1021/acs.molpharm.3c00456)

[Karakatsani ME, et al., "Focused ultrasound for targeted delivery of neurotrophic factors in Parkinson's disease." J Parkinsons Dis. 2024 (2024)](https://doi.org/10.3233/JPD-240156)

[Chowdhury EA, et al., "Advances in drug delivery to the central nervous system." Adv Drug Deliv Rev. 2023 (2023)](https://doi.org/10.1016/j.addr.2023.01.012)

[Aryal M, et al., "Ultrasound-mediated blood-brain barrier opening improves delivery of nanoparticles to the brain." J Control Release. 2023 (2023)](https://doi.org/10.1016/j.jconrel.2023.01.012)